Preliminary Phase I data for Nkarta, Inc.’s allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapies suggest the firm could have a strong showing in the CAR-NK race overall. The early data show strong response rates and depth of responses that could provide an indication of durability.
Nkarta Unveils Early But Promising Data For CAR-NK Therapies In AML, NHL
NKX101 in acute myeloid leukemia and NKX019 in non-Hodgkin’s lymphoma showed high complete response rates, but without the toxicity associated with CAR-Ts.
